Literature DB >> 26707759

Predictive factors associated with increased progression to dialysis in early chronic kidney disease (stage 1-3) patients.

Nao Nohara1, Hiroaki Io1, Mayumi Matsumoto1, Masako Furukawa1, Kozue Okumura1, Junichiro Nakata1, Yoshio Shimizu1, Satoshi Horikoshi1, Yasuhiko Tomino2.   

Abstract

BACKGROUND: It has been reported that echocardiographic parameters are independently associated with the progression to dialysis in patients with chronic kidney disease (CKD) (stages 3-5). The objective of the present study was to evaluate whether physical, biochemical, and echocardiographic parameters are associated with the progression to dialysis in early CKD (stage 1-3) patients.
METHODS: This retrospective study enrolled 272 CKD patients who underwent echocardiography at the time of diet education, renal biopsy, and the examination of kidney injuries at Juntendo University Hospital, Tokyo, Japan, from 2001 to 2010. All of these CKD patients were classified into stages 1-3. The study patients received regular follow-up at our outpatient clinic in our division. The renal end point was defined as commencement of dialysis.
RESULTS: Patients with progression to dialysis were significantly associated with higher levels of left ventricular mass index (LVMI), urinary protein, systolic blood pressure, many kinds of anti-hypertensive drugs, and lower levels of albumin and hemoglobin. In a Cox proportional hazard regression analysis, LVMI [hazard ration (HR) 1.018; 95 % confidence interval (CI) 1.007-1.029; p = 0.002], urinary protein and hemoglobin were independently associated with factors for progression to dialysis in early CKD patients.
CONCLUSION: This study of patients in early CKD demonstrated that higher LVMI and urinary protein and that lower levels of hemoglobin in blood were associated with progression to dialysis. LVMI evaluated by echocardiography may identify a high risk of progression to dialysis in early CKD patients.

Entities:  

Keywords:  Anemia; Early chronic kidney disease (CKD) stage; Echocardiography; Left ventricular mass index (LVMI)

Mesh:

Substances:

Year:  2015        PMID: 26707759     DOI: 10.1007/s10157-015-1210-3

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  30 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Is left ventricular hypertrophy a powerful predictor of progression to dialysis in chronic kidney disease?

Authors:  Ernesto Paoletti; Diego Bellino; Anna Maria Gallina; Marco Amidone; Paolo Cassottana; Giuseppe Cannella
Journal:  Nephrol Dial Transplant       Date:  2010-07-13       Impact factor: 5.992

Review 3.  Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment.

Authors:  F Locatelli; J Bommer; G M London; A Martín-Malo; C Wanner; M Yaqoob; C Zoccali
Journal:  Nephrol Dial Transplant       Date:  2001-03       Impact factor: 5.992

Review 4.  Left ventricular mass in chronic kidney disease and ESRD.

Authors:  Richard J Glassock; Roberto Pecoits-Filho; Silvio H Barberato
Journal:  Clin J Am Soc Nephrol       Date:  2009-12       Impact factor: 8.237

5.  Anemia as a risk factor for kidney function decline in individuals with heart failure.

Authors:  Nisha Bansal; Hocine Tighiouart; Daniel Weiner; John Griffith; Panagiotis Vlagopoulos; Deeb Salem; Adeera Levin; Mark J Sarnak
Journal:  Am J Cardiol       Date:  2007-03-07       Impact factor: 2.778

Review 6.  Pathogenesis and therapeutic implications of cardiorenal syndrome.

Authors:  Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2010-11-23       Impact factor: 2.801

7.  Predictive factors associated with change rates of LV hypertrophy and renal dysfunction in CKD patients.

Authors:  Kozue Okumura; Hiroaki Io; Mayumi Matsumoto; Takuya Seto; Miyuki Takagi; Atsumi Masuda; Masako Furukawa; Lili Nagahama; Keisuke Omote; Atsuko Hisada; Chieko Hamada; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  Clin Nephrol       Date:  2013-01       Impact factor: 0.975

8.  The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study.

Authors:  William F Keane; Barry M Brenner; Dick de Zeeuw; Jean-Pierre Grunfeld; Janet McGill; William E Mitch; Artur B Ribeiro; Shahnaz Shahinfar; Roger L Simpson; Steven M Snapinn; Robert Toto
Journal:  Kidney Int       Date:  2003-04       Impact factor: 10.612

9.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.

Authors:  S Klahr; A S Levey; G J Beck; A W Caggiula; L Hunsicker; J W Kusek; G Striker
Journal:  N Engl J Med       Date:  1994-03-31       Impact factor: 91.245

10.  Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study.

Authors:  Emanuele Di Angelantonio; Rajiv Chowdhury; Nadeem Sarwar; Thor Aspelund; John Danesh; Vilmundur Gudnason
Journal:  BMJ       Date:  2010-09-30
View more
  3 in total

1.  Plasma neutrophil gelatinase-associated lipocalin (NGAL) is an indicator of interstitial damage and a predictor of kidney function worsening of chronic kidney disease in the early stage: a pilot study.

Authors:  Hidekazu Moriya; Yasuhiro Mochida; Kunihiko Ishioka; Machiko Oka; Kyoko Maesato; Sumi Hidaka; Takayasu Ohtake; Shuzo Kobayashi
Journal:  Clin Exp Nephrol       Date:  2017-04-10       Impact factor: 2.801

2.  Left ventricular myocardial mass index associated with cardiovascular and renal prognosis in IgA nephropathy.

Authors:  Balázs Sági; István Késői; Tibor Vas; Botond Csiky; Judit Nagy; Tibor József Kovács
Journal:  BMC Nephrol       Date:  2022-08-16       Impact factor: 2.585

Review 3.  Challenging patient phenotypes in the management of anaemia of chronic kidney disease.

Authors:  Sheena Pramod; David S Goldfarb
Journal:  Int J Clin Pract       Date:  2021-08-12       Impact factor: 3.149

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.